Oncolytic virus-mediated reversal of impaired tumor antigen presentation

Frontiers in Oncology

Volumn 4 APR, Issue , 2014, Pages

  Gujar, Shashi A ^a,b   Lee, Patrick W K ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b IWK HEALTH CENTRE   (Canada)

Author keywords

Anti tumor immunity; Antigen presentation; Immunotherapy; Oncolytic virus; Reovirus

Indexed keywords

ALPHA INTERFERON; B7 ANTIGEN; BETA 2 MICROGLOBULIN; BETA INTERFERON; CD30 LIGAND; CD40 LIGAND; CD86 ANTIGEN; EOTAXIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 3; MONOCYTE CHEMOTACTIC PROTEIN 5; ONCOLYTIC VIRUS; RANTES; VASCULAR CELL ADHESION MOLECULE 1;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INTERACTION; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX; NEOPLASM; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

EID: 84901022638     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00077     Document Type: Article

References (84)

1. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol (2012) 12:269-81. doi: 10.1038/nri3191.
2. McKee MD, Fichera A, Nishimura MI. T cell immunotherapy. Front Biosci (2007) 12:919-32. doi:10.2741/2114.
3. Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer (2014) 14:135-46. doi:10.1038/nrc3670.
4. Kalos M, June CH. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity (2013) 39:49-60. doi:10.1016/j.immuni.2013.07.002.
5. Hanada K, Restifo NP. Double or nothing on cancer immunotherapy. Nat Biotechnol (2013) 31:33-4. doi:10.1038/nbt.2471.
6. Couzin-Frankel J. The dizzying journey to a new cancer arsenal. Science (2013) 340:1514-8. doi:10.1126/science.340.6140.1514.
7. Kershaw MH, Westwood JA, Darcy PK. Gene-engineered T cells for cancer therapy. Nat Rev Cancer (2013) 13:525-41. doi:10.1038/nrc3565.
8. Miest TS, Cattaneo R. New viruses for cancer therapy: meeting clinical needs. Nat Rev Microbiol (2014) 12:23-34. doi:10.1038/nrmicro3140.
9. Patel MR, Kratzke RA. Oncolytic virus therapy for cancer: the first wave of translational clinical trials. Transl Res (2013) 161:355-64. doi:10.1016/j.trsl.2012.12.010.
10. Hiss DC, Fielding BC. Optimization and preclinical design of genetically engineered viruses for human oncolytic therapy. Expert Opin Biol Ther (2012) 12:1427-47. doi:10.1517/14712598.2012.707183.
11. Zeyaullah M, Patro M, Ahmad I, Ibraheem K, Sultan P, Nehal M, et al. Oncolytic viruses in the treatment of cancer: a review of current strategies. Pathol Oncol Res (2012) 18:771-81. doi:10.1007/s12253-012-9548-2.
12. Donnelly OG, Errington-Mais F, Prestwich R, Harrington K, Pandha H, Vile R, et al. Recent clinical experience with oncolytic viruses. Curr Pharm Biotechnol (2012) 13:1834-41. doi:10.2174/138920112800958904.
13. Cerullo V, Koski A, Vaha-Koskela M, Hemminki A. Chapter eight-oncolytic adenoviruses for cancer immunotherapy: data from mice, hamsters, and humans. Adv Cancer Res (2012) 115:265-318. doi:10.1016/B978-0-12-398342-8.00008-2.
14. Melcher A, Parato K, Rooney CM, Bell JC. Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol Ther (2011) 19:1008-16. doi:10.1038/mt.2011.65.
15. Bridle BW, Hanson S, Lichty BD. Combining oncolytic virotherapy and tumour vaccination. Cytokine Growth Factor Rev (2010) 21:143-8. doi:10.1016/j.cytogfr.2010.02.009.
16. Galivo F, Diaz RM, Thanarajasingam U, Jevremovic D, Wongthida P, Thompson J, et al. Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus. Hum Gene Ther (2010) 21:439-50. doi:10.1089/hum.2009.143.
17. Gujar S, Dielschneider R, Clements D, Helson E, Shmulevitz M, Marcato P, et al. Multifaceted therapeutic targeting of ovarian peritoneal carcinomatosis through virus-induced immunomodulation. Mol Ther (2013) 21:338-47. doi:10.1038/mt.2012.228.
18. Todo T. Active immunotherapy: oncolytic virus therapy using HSV-1. Adv Exp Med Biol (2012) 746:178-86. doi:10.1007/978-1-4614-3146-6_14.
19. Zhao L, Liu H. Newcastle disease virus: a promising agent for tumour immunotherapy. Clin Exp Pharmacol Physiol (2012) 39:725-30. doi:10.1111/j.1440-1681.2011.05662.x.
20. Prestwich RJ, Errington F, Diaz RM, Pandha HS, Harrington KJ, Melcher AA, et al. The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Hum Gene Ther (2009) 20:1119-32. doi:10.1089/hum.2009.135.
21. Janeway C, Travers P, Walport M, Shlomchick M. Immunobiology: The Immune System in Health and Disease. New York, NY: Garland Publishing (2001).
22. Varga SM, Braciale TJ. The adaptive immune response to respiratory syncytial virus. Curr Top Microbiol Immunol (2013) 372:155-71. doi:10.1007/978-3-642-38919-1_8.
23. Wiesel M, Oxenius A. From crucial to negligible: functional CD8(+) T-cell responses and their dependence on CD4(+) T-cell help. Eur J Immunol (2012) 42:1080-8. doi:10.1002/eji.201142205.
24. Swain SL, McKinstry KK, Strutt TM. Expanding roles for CD4(+) T cells in immunity to viruses. Nat Rev Immunol (2012) 12:136-48. doi:10.1038/nri3152.
25. Sant AJ, McMichael A. Revealing the role of CD4(+) T cells in viral immunity. J Exp Med (2012) 209:1391-5. doi:10.1084/jem.20121517.
26. Whitmire JK. Induction and function of virus-specific CD4+ T cell responses. Virology (2011) 411:216-28. doi:10.1016/j.virol.2010.12.015.
27. Brouwenstijn N, Serwold T, Shastri N. MHC class I molecules can direct proteolytic cleavage of antigenic precursors in the endoplasmic reticulum. Immunity (2001) 15:95-104. doi:10.1016/S1074-7613(01)00174-1.
28. Reits E, Griekspoor A, Neijssen J, Groothuis T, Jalink K, van Veelen P, et al. Peptide diffusion, protection, and degradation in nuclear and cytoplasmic compartments before antigen presentation by MHC class I. Immunity (2003) 18:97-108. doi:10.1016/S1074-7613(02)00511-3.
29. Yaneva R, Schneeweiss C, Zacharias M, Springer S. Peptide binding to MHC class I and II proteins: new avenues from new methods. Mol Immunol (2010) 47:649-57. doi:10.1016/j.molimm.2009.10.008.
30. Leone P, Shin EC, Perosa F, Vacca A, Dammacco F, Racanelli V. MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells. J Natl Cancer Inst (2013) 105:1172-87. doi:10.1093/jnci/djt184.
31. Murphy K, Janeway C, Travers P, Walport M, Mowat A, Weaver C. Janeway's Immunobiology. New York, NY: Garland Science, Taylor and Francis group, LLC (2011).
32. Jung S, Unutmaz D, Wong P, Sano G, De los Santos K, Sparwasser T, et al. In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens. Immunity (2002) 17:211-20. doi:10.1016/S1074-7613(02)00365-5.
33. Joffre OP, Segura E, Savina A, Amigorena S. Cross-presentation by dendritic cells. Nat Rev Immunol (2012) 12:557-69. doi:10.1038/nri3254.
34. Heath WR, Carbone FR. Cross-presentation in viral immunity and self-tolerance. Nat Rev Immunol (2001) 1:126-34. doi:10.1038/35100512.
35. Heath WR, Belz GT, Behrens GMN, Smith CM, Forehan SP, Parish IA, et al. Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. mmunol Rev (2004) 199:9-26. doi:10.1111/j.0105-2896.2004.00142.x.
36. Walter W, Lingnau K, Schmitt E, Loos M, Maeurer MJ. MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance? Br J Cancer (2000) 83:1192-201. doi:10.1054/bjoc.2000.1415.
37. Braciale TJ, Morrison LA, Sweetser MT, Sambrook J, Gething MJ, Braciale VL. Antigen presentation pathways to class I and class II MHC-restricted T lymphocytes. Immunol Rev (1987) 98:95-114. doi:10.1111/j.1600-065X.1987.tb00521.x.
38. Gannage M, Munz C. MHC presentation via autophagy and how viruses escape from it. Semin Immunopathol (2010) 32:373-81. doi:10.1007/s00281-010-0227-7.
39. Bour-Jordan H, Esensten JH, Martinez-Llordella M, Penaranda C, Stumpf M, Bluestone JA. Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/B7 family. Immunol Rev (2011) 241:180-205. doi:10.1111/j.1600-065X.2011.01011.x.
40. Nurieva RI, Liu X, Dong C. Yin-Yang of costimulation: crucial controls of immune tolerance and function. Immunol Rev (2009) 229:88-100. doi:10.1111/j.1600-065X.2009.00769.x.
41. Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol (2002) 2:116-26. doi:10.1038/nri727.
42. Sharpe AH. Mechanisms of costimulation. Immunol Rev (2009) 229:5-11. doi:10.1111/j.1600-065X.2009.00784.x.
43. Curtsinger JM, Mescher MF. Inflammatory cytokines as a third signal for T cell activation. Curr Opin Immunol (2010) 22:333-40. doi:10.1016/j.coi.2010.02.013.
44. Hervas-Stubbs S, Riezu-Boj JI, Gonzalez I, Mancheno U, Dubrot J, Azpilicueta A, et al. Effects of IFN-alpha as a signal-3 cytokine on human naive and antigen-experienced CD8(+) T cells. Eur J Immunol (2010) 40:3389-402. doi:10.1002/eji.201040664.
45. Gerner MY, Heltemes-Harris LM, Fife BT, Mescher MF. Cutting edge: IL-12 and type I IFN differentially program CD8 T cells for programmed death 1 re-expression levels and tumor control. J Immunol (2013) 191:1011-5. doi:10.4049/jimmunol.1300652.
46. Hervas-Stubbs S, Perez-Gracia JL, Rouzaut A, Sanmamed MF, Le Bon A, Melero I. Direct effects of type I interferons on cells of the immune system. Clin Cancer Res (2011) 17:2619-27. doi:10.1158/1078-0432.CCR-10-1114.
47. Xiao Z, Casey KA, Jameson SC, Curtsinger JM, Mescher MF. Programming for CD8 T cell memory development requires IL-12 or type I IFN. J Immunol (2009) 182:2786-94. doi:10.4049/jimmunol.0803484.
48. Ben-Sasson SZ, Hu-Li J, Quiel J, Cauchetaux S, Ratner M, Shapira I, et al. IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation. Proc Natl Acad Sci U S A (2009) 106:7119-24. doi:10.1073/pnas.0902745106.
49. MacLeod MK, Kappler JW, Marrack P. Memory CD4 T cells: generation, reactivation and re-assignment. Immunology (2010) 130:10-5. doi:10.1111/j.1365-2567.2010.03260.x.
50. Hikono H, Kohlmeier JE, Ely KH, Scott I, Roberts AD, Blackman MA, et al. T-cell memory and recall responses to respiratory virus infections. Immunol Rev (2006) 211:119-32. doi:10.1111/j.0105-2896.2006.00385.x.
51. Motz GT, Coukos G. Deciphering and reversing tumor immune suppression. Immunity (2013) 39:61-73. doi:10.1016/j.immuni.2013.07.005.
52. Hargadon KM. Tumor-altered dendritic cell function: implications for anti-tumor immunity. Front Immunol (2013) 4:192. doi:10.3389/fimmu.2013.00192.
53. Horst D, Verweij MC, Davison AJ, Ressing ME, Wiertz EJ. Viral evasion of T cell immunity: ancient mechanisms offering new applications. Curr Opin Immunol (2011) 23:96-103. doi:10.1016/j.coi.2010.11.005.
54. Charbonneau B, Goode EL, Kalli KR, Knutson KL, Derycke MS. The immune system in the pathogenesis of ovarian cancer. Crit Rev Immunol (2013) 33:137-64. doi:10.1615/CritRevImmunol.2013006813.
55. Thibodeau J, Bourgeois-Daigneault MC, Lapointe R. Targeting the MHC class II antigen presentation pathway in cancer immunotherapy. Oncoimmunology (2012) 1:908-16. doi:10.4161/onci.21205.
56. Michel S, Linnebacher M, Alcaniz J, Voss M, Wagner R, Dippold W, et al. Lack of HLA class II antigen expression in microsatellite unstable colorectal carcinomas is caused by mutations in HLA class II regulatory genes. Int J Cancer (2010) 127:889-98. doi:10.1002/ijc.25106.
57. Meissner M, Whiteside TL, van Kuik-Romein P, Valesky EM, van den Elsen PJ, Kaufmann R, et al. Loss of interferon-gamma inducibility of the MHC class II antigen processing pathway in head and neck cancer: evidence for post-transcriptional as well as epigenetic regulation. Br J Dermatol (2008) 158:930-40. doi:10.1111/j.1365-2133.2008.08465.x.
58. Ting JP, Trowsdale J. Genetic control of MHC class II expression. Cell (2002) 109(Suppl):S21-33. doi:10.1016/S0092-8674(02)00696-7.
59. Martin-Orozco N, Dong C. Inhibitory costimulation and anti-tumor immunity. Semin Cancer Biol (2007) 17:288-98. doi:10.1016/j.semcancer.2007.06.003.
60. Kumar H, Kawai T, Akira S. Pathogen recognition by the innate immune system. Int Rev Immunol (2011) 30:16-34. doi:10.3109/08830185.2010.529976.
61. Akira S, Saitoh T, Kawai T. Nucleic acids recognition by innate immunity. Uirusu (2012) 62:39-45. doi:10.2222/jsv.62.39.
62. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on toll-like receptors. Nat Immunol (2010) 11:373-84. doi:10.1038/ni.1863.
63. Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity (2011) 34:637-50. doi:10.1016/j.immuni.2011.05.006.
64. Kawai T, Akira S. The roles of TLRs, RLRs and NLRs in pathogen recognition. Int Immunol (2009) 21:317-37. doi:10.1093/intimm/dxp017.
65. Montoya M, Schiavoni G, Mattei F, Gresser I, Belardelli F, Borrow P, et al. Type I interferons produced by dendritic cells promote their phenotypic and functional activation. Blood (2002) 99:3263-71. doi:10.1182/blood.V99.9.3263.
66. Rudd BD, Luker GD, Luker KE, Peebles RS, Lukacs NW. Type I interferon regulates respiratory virus infected dendritic cell maturation and cytokine production. Viral Immunol (2007) 20:531-40. doi:10.1089/vim.2007.0057.
67. Kawai T, Akira S. Innate immune recognition of viral infection. Nat Immunol (2006) 7:131-7. doi:10.1038/ni1303.
68. Rock KL, Shen L. Cross-presentation: underlying mechanisms and role in immune surveillance. Immunol Rev (2005) 207:166-83. doi:10.1111/j.0105-2896.2005.00301.x.
69. Boisgerault N, Tangy F, Gregoire M. New perspectives in cancer virotherapy: bringing the immune system into play. Immunotherapy (2010) 2:185-99. doi:10.2217/imt.10.6.
70. Prestwich RJ, Harrington KJ, Pandha HS, Vile RG, Melcher AA, Errington F. Oncolytic viruses: a novel form of immunotherapy. Expert Rev Anticancer Ther (2008) 8:1581-8. doi:10.1586/14737140.8.10.1581.
71. Gujar SA, Marcato P, Pan D, Lee PW. Reovirus virotherapy overrides tumor antigen presentation evasion and promotes protective antitumor immunity. Mol Cancer Ther (2010) 9:2924-33. doi:10.1158/1535-7163.MCT-10-0590.
72. Guillerme JB, Boisgerault N, Roulois D, Menager J, Combredet C, Tangy F, et al. Measles virus vaccine-infected tumor cells induce tumor antigen cross-presentation by human plasmacytoid dendritic cells. Clin Cancer Res (2013) 19:1147-58. doi:10.1158/1078-0432.CCR-12-2733.
73. Wongthida P, Diaz RM, Pulido C, Rommelfanger D, Galivo F, Kaluza K, et al. Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus. Hum Gene Ther (2011) 22:1343-53. doi:10.1089/hum.2010.216.
74. Lindenmann J, Klein PA. Viral oncolysis: increased immunogenicity of host cell antigen associated with influenza virus. J Exp Med (1967) 126:93-108. doi:10.1084/jem.126.1.93.
75. Shmulevitz M, Lee PW. Exploring host factors that impact reovirus replication, dissemination, and reovirus-induced cell death in cancer versus normal cells in culture. Methods Mol Biol (2012) 797:163-76. doi:10.1007/978-1-61779-340-0_12.
76. Fonteneau JF, Guillerme JB, Tangy F, Gregoire M. Attenuated measles virus used as an oncolytic virus activates myeloid and plasmacytoid dendritic cells. Oncoimmunology (2013) 2:e24212. doi:10.4161/onci.24212.
77. Benencia F, Courreges MC, Fraser NW, Coukos G. Herpes virus oncolytic therapy reverses tumor immune dysfunction and facilitates tumor antigen presentation. Cancer Biol Ther (2008) 7:1194-205. doi:10.4161/cbt.7.8.6216.
78. Greiner S, Humrich JY, Thuman P, Sauter B, Schuler G, Jenne L. The highly attenuated vaccinia virus strain modified virus Ankara induces apoptosis in melanoma cells and allows bystander dendritic cells to generate a potent anti-tumoral immunity. Clin Exp Immunol (2006) 146:344-53. doi:10.1111/j.1365-2249.2006.03177.x.
79. Errington F, Steele L, Prestwich R, Harrington KJ, Pandha HS, Vidal L, et al. Reovirus activates human dendritic cells to promote innate antitumor immunity. J Immunol (2008) 180:6018-26.
80. Todo T, Martuza RL, Rabkin SD, Johnson PA. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci U S A (2001) 98:6396-401. doi:10.1073/pnas.101136398.
81. Schierer S, Hesse A, Knippertz I, Kaempgen E, Baur AS, Schuler G, et al. Human dendritic cells efficiently phagocytose adenoviral oncolysate but require additional stimulation to mature. Int J Cancer (2012) 130:1682-94. doi:10.1002/ijc.26176.
82. Leveille S, Goulet ML, Lichty BD, Hiscott J. Vesicular stomatitis virus oncolytic treatment interferes with tumor-associated dendritic cell functions and abrogates tumor antigen presentation. J Virol (2011) 85:12160-9. doi:10.1128/JVI.05703-11.
83. Hansen TH, Bouvier M. MHC class I antigen presentation: learning from viral evasion strategies. Nat Rev Immunol (2009) 9:503-13. doi:10.1038/nri2575.
84. Ressing ME, Luteijn RD, Horst D, Wiertz EJ. Viral interference with antigen presentation: trapping TAP. Mol Immunol (2013) 55:139-42. doi:10.1016/j.molimm.2012.10.009.